Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer

1236PAMRUBICIN (AMR) VERSUS DOCETAXEL (DTX) AS SECOND- OR THIRD-LINE TREATMENT FOR NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III TRIAL

(2017) N. Katakami et al.   ANNALS OF ONCOLOGY

ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer

(2014) K Shimizu et al.   BRITISH JOURNAL OF CANCER

Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation

(2013) Shuji Murakami et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402

(2012) Naoyuki Nogami et al.   ACTA ONCOLOGICA

The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy

(2012) Kyoichi Kaira et al.   International Journal of Clinical Oncology

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

(2011) Christopher G. Azzoli et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of amrubicin and vinorelbine in non-small cell lung cancer previously treated with platinum-based chemotherapy

(2009) Satoshi Oizumi et al.   International Journal of Clinical Oncology

A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer

(2009) Kyoichi Kaira et al.   LUNG CANCER

Excision Repair Cross Complementing-1 and Topoisomerase IIα Gene Expression in Small-Cell Lung Cancer Patients Treated with Platinum and Etoposide: A Retrospective Study

(2008) Paolo Ceppi et al.   Journal of Thoracic Oncology